Innovent Biologics (IVBXF) Stock Price, News & Analysis

Company Overview

Innovent Biologics is a biopharmaceutical company headquartered in Suzhou, China, specializing in the development, manufacturing and commercialization of high-quality monoclonal antibodies. Since its founding in 2011, the company has focused on creating both novel biologics and biosimilars targeting oncology, autoimmune disorders and cardiovascular diseases. Innovent operates integrated R&D facilities and manufacturing sites that adhere to global regulatory standards, supporting end-to-end drug development from discovery through commercial launch.

The company’s commercial portfolio includes marketed products such as sintilimab (marketed as Tyvyt in collaboration with Eli Lilly), a PD-1 inhibitor approved for various indications in China, and several biosimilar antibodies against targets like VEGF and CD20. In addition to its marketed drugs, Innovent maintains a robust pipeline comprising more than 20 candidates in various stages of clinical development. These pipeline assets address key therapeutic areas including solid tumors, hematological malignancies and inflammatory diseases.

Innovent has established strategic partnerships with global pharmaceutical companies to accelerate the development and distribution of its therapies. Its collaboration with Eli Lilly encompasses development, regulatory filing and commercialization for multiple indications both within China and in select international markets. The company also collaborates with European and U.S. research institutions to expand its scientific capabilities and foster innovation across its antibody platform.

Serving primarily the Chinese market, Innovent is expanding its global footprint by seeking approvals and forging partnerships in Asia, Europe and North America. Under the leadership of founder and chairman Dr. Michael Yu, the company emphasizes patient access, cost-effective manufacturing and scientific rigor. Innovent’s integrated approach aims to bring accessible, cutting-edge biologic therapies to patients worldwide.

Key Stats

• Today's Range: $11.35 to $12.00
• 50-Day Range: $5.94 to $11.50
• 52-Week Range: $3.91 to $12.09
• Volume: 4,100 shs
• Average Volume: 33,205 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IVBXF Stock Analysis - Frequently Asked Questions

How have IVBXF shares performed this year?

Innovent Biologics' stock was trading at $4.50 at the beginning of 2025. Since then, IVBXF shares have increased by 164.4% and is now trading at $11.90.

How do I buy shares of Innovent Biologics?

Shares of IVBXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/22/2025
• Next Earnings (Estimated): 8/26/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:IVBXF
• CIK: N/A
• Web: www.innoventbio.com
• Phone: 86-512-6956-6088
• Fax: N/A
• Employees: 4,872
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A